AI-assisted approach identifies IRS4 as a promising drug target in multiple solid tumors

Leveraging AI capabilities combined with genetic data led St. Jude Children’s Research Hospital investigators to predict new cancer drug targets that carry a limited risk of side effects. For their study, published in Science Advances, St. Jude Children’s Research Hospital scientists used a mix of genetic cancer dependency data, artificial intelligence (AI), and naturally occurring mutations to prioritize safer cancer drug targets.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup